Syndax Pharmaceuticals (SNDX) Earnings Date & Reports

Key Takeaways

• Total revenue for the third quarter of 2026 reached $83.3 million, topping analyst expectations of roughly $82 million.
• Net loss attributable to common stockholders was $49.4 million, or $0.55 per share, wider than the $0.48 consensus loss estimate.
• Revuforj (revumenib) delivered $60.7 million in net revenue, with NPM1-mutated acute myeloid leukemia (AML) patients fueling roughly 35% of quarterly sales.
• Niktimvo (axatilimab-csfr) generated $67.4 million in net revenue, a 47% year-over-year increase, while Syndax booked $22.6 million in collaboration revenue.
• The company ended the quarter with $551.1 million in cash, cash equivalents, and investments, and reaffirmed full-year 2026 operating expense guidance.
• For more context on the company's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages.
• Explore Trending AI Robots to see AI-driven strategies traders are watching across the market.

Earnings Context and Why It Matters

Syndax Pharmaceuticals (SNDX) is a commercial-stage biopharmaceutical company advancing cancer therapies, anchored by two launched medicines: Revuforj for certain genetically defined acute leukemias and Niktimvo for chronic graft-versus-host disease (cGVHD), a complication of stem cell transplants. Because the company is still investing heavily in research and development (R&D) to expand both drugs into earlier treatment lines, investors closely track revenue momentum and launch execution rather than bottom-line profitability. This quarter's results matter because they show how quickly Revuforj's NPM1-mutant AML launch is scaling and whether Niktimvo's commercial buildout with partner Incyte remains on track, two signals that frame Syndax's path toward profitability.

Reported Results

For the third quarter of 2026, ended September 30, 2026, Syndax reported total revenue of $83.3 million, consisting of $60.7 million in Revuforj net revenue and $22.6 million in Niktimvo collaboration revenue. This exceeded the consensus estimate of approximately $82 million. Niktimvo net revenue reached $67.4 million, up 47% from the prior-year quarter and 12% sequentially.

On the bottom line, the company posted a net loss attributable to common stockholders of $49.4 million, or $0.55 per share, compared with a loss of $60.7 million, or $0.70 per share, a year earlier. The per-share result fell short of the $0.48 loss analysts had modeled. R&D expenses rose to $67.5 million from $56.3 million, driven by frontline trials of revumenib in AML, while selling, general and administrative (SG&A) expenses declined modestly to $43.7 million. Syndax reiterated that it expects full-year 2026 combined R&D and SG&A expenses of approximately $400 million, excluding about $50 million in non-cash stock compensation.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like Syndax Pharmaceuticals, the AI Screener offers a practical way to identify comparable opportunities and monitor shifting market conditions.

Market Reaction and Investor Sentiment

Syndax shares closed at $13.10 and traded lower in the after-hours session, dipping roughly 2% toward $12.80 following the report. The mixed result, a revenue beat paired with a wider-than-expected loss, reflects investor focus on both the strength of Revuforj's launch and the elevated spending tied to expanding its label into frontline AML. Management emphasized that NPM1-mutant patients now account for more than 35% of quarterly Revuforj net revenue and that the drug holds a dominant share of new menin inhibitor prescriptions. Those commercial signals have supported sentiment, even as heavier R&D investment continues to weigh on near-term profitability and keeps the company in a net-loss position.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will be watching how Revuforj's NPM1-mutant AML launch matures. Management highlighted that roughly 40% of NPM1 patients are now proceeding to stem cell transplant, with about half resuming therapy afterward, a pattern that could extend average treatment duration and support durable revenue growth over time.

On the Niktimvo side, Syndax and Incyte continue to co-commercialize the cGVHD therapy, with Syndax recording 50% of net commercial profit. Sustained sequential growth here will be an important complement to Revuforj's trajectory as the company works toward profitability.

Cost control and clinical development spending remain central themes. The company has reaffirmed full-year 2026 operating expense guidance of about $400 million, excluding non-cash stock compensation, while advancing frontline combination trials for revumenib. Investors should monitor enrollment progress, upcoming data readouts, and any shifts in the competitive menin inhibitor landscape, all of which could influence both the pace of spending and the long-term revenue opportunity. As always, this is not a forecast of stock price performance, but a framework of known catalysts and financial signals worth following.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations